Vor Biopharma (Nasdaq: VOR), a cell and genome engineering company, today announced that Robert Ang, M.B.B.S., MBA, Vor’s President and Chief Executive Officer, and Nathan Jorgensen, Ph.D., Vor’s Chief Financial Officer, will be participating in two upcoming virtual investor conferences:
Stifel 2021 Virtual Healthcare Conference
Fireside Chat Date: Monday, November 15, 2021
Time: 4:00 PM ET
Evercore ISI 4th Annual HealthCONx Virtual Conference
Fireside Chat Date: Thursday, December 2, 2021
Time: 10:55 AM ET
A live webcast of both fireside chats can be accessed via the Investors section of the Company's website at www.vorbio.com. An archived replay of each webcast will also be available.
About Vor Biopharma
Vor Biopharma is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.
Contacts:
Investors:
Chris Brinzey
ICR Westwicke
+1 339-970-2843
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media:
Sarah Spencer
+1 857-242-6076
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.60 |
| Daily Change: | -0.14 -8.05 |
| Daily Volume: | 6,102,541 |
| Market Cap: | US$202.690M |
August 27, 2025 July 21, 2025 June 25, 2025 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
